We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00168727
First Posted: September 15, 2005
Last Update Posted: October 19, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Biogen
  Purpose
The purpose of this study is to determine the safety and effectiveness of a treatment regimen using Zevalin® plus Rituxan® for patients who have low grade Non-Hodgkin’s Lymphoma (NHL) or relapsed Non-Hodgkin’s lymphoma and have been previously treated. This study will use an experimental scheduling regimen. No chemotherapy will be used in this study.

Condition Intervention Phase
Lymphoma, Non-Hodgkin Lymphoma, Low-Grade Drug: ibritumomab tiuxetan (Zevalin®) Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma

Resource links provided by NLM:


Further study details as provided by Biogen:

Primary Outcome Measures:
  • Determine overall response rate, event-free survival, time-to-progression, time-to-next-therapy, and freedom-from-relapse in pts with low-grade lymphoma in first or second relapse treated with Zevalin® followed by 2 yrs of Rituxan maintenance therapy

Secondary Outcome Measures:
  • Evaluate relative response rates in populations with and without prior rituximab therapy, in first versus second relapse, and with and without bulky (> 5 cm in greatest diameter) disease.

Estimated Enrollment: 12
Study Start Date: June 2003
Estimated Study Completion Date: October 2005
Detailed Description:

The objective of this study is to determine overall response rate, event-free survival, time-to-progression, time-to-next-therapy, and freedom-from-relapse in patients with low-grade lymphoma in first or second relapse treated with Zevalin followed by 2 years of Rituxan maintenance therapy in a multicenter, community-based setting, as well as evaluate relative response rates in populations with and without prior rituximab therapy, in first versus second relapse, and with and without bulky (> 5 cm in greatest diameter) disease.

To meet the initial trial enrollment goal of 300 patients over two years, 42 total sites were activated. The study has subsequently closed to accrual. Currently 8 sites remain active to follow the 12 subjects enrolled in the past year.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Follicular non-Hodgkin’s lymphoma including SLL in first or second relapse.
  • No anticancer therapy for three wks (six wks if nitrosourea or Mitomycin C); not rituximab refractory.
  • Age >= 18 years, not pregnant or lactating.
  • Expected survival >= 3 mths; PS 0, 1, or 2.
  • ANC >= 1,500/mm3, platelet counts >= 100,000/mm3.
  • Total bilirubin > 2.0 mg/dL, creatinine > 2.0 mg/dL.
  • Total lymphocyte count < 5,000/mm3 for SLL.
  • <25% bone marrow involvement with lymphoma.

Exclusion Criteria:

  • Prior ABMT or ASCT, hypocellular or marked reduction in bone marrow precursors, or history of failed stem cell collection.
  • Bulky areas of disease more than 10 cm in diameter.
  • Patients with CLL, CNS, or mantle cell lymphoma.
  • Hx of HIV/AIDS related lymphoma, hepatitis B or C.
  • Prior radioimmunotherapy or XRT to >25% of active bone marrow.
  • G-CSF or GM-CSF within 2 wks, pegylated G-CSF within 4 wks of treatment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168727


Locations
United States, California
Loma Linda University
Loma Linda, California, United States
North County Oncology
Oceanside, California, United States
United States, Connecticut
Medical Specialists of Fairfield
Fairfield, Connecticut, United States
United States, Hawaii
Queens Hospital
Honolulu, Hawaii, United States
United States, Illinois
Northwest Oncology and Hematology
Elk Grove Village, Illinois, United States
United States, Indiana
Horizon Oncolgy Center
Lafayette, Indiana, United States
United States, Missouri
Specialists in Hematology/Oncology
St. Louis, Missouri, United States
United States, North Carolina
Presbyterian Hospital Cancer Center
Charlotte, North Carolina, United States
Sponsors and Collaborators
Biogen
Investigators
Study Director: Wayne Saville Biogen
  More Information

ClinicalTrials.gov Identifier: NCT00168727     History of Changes
Other Study ID Numbers: 001-03-ZEV
Former Biogen Idec: 106-I001
First Submitted: September 13, 2005
First Posted: September 15, 2005
Last Update Posted: October 19, 2006
Last Verified: October 2006

Keywords provided by Biogen:
Radioimmunotherapy
Antigens, CD20

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rituximab
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents